AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23780378 — intervention group
Group type: COMPARATOR
Intervention: Aspiration alone
Number of subjects: 44
Study 20625263 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus standard-dose lopinavir/ritonavir (LPV/r) 300 mg zidovudine and 400/100 mg LPV/r twice daily from 28 weeks' gestation until delivery
Number of subjects: 38
Study 18974537 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: necrotic coronal pulp removal
Number of subjects: 60
Study 18974537 — intervention group
Group type: COMPARATOR
Intervention: Group B: necrotic coronal and accessible radicular pulp removal
Number of subjects: 60
Study 19478654 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 50
Study 19478654 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 50
Study 15731312 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Crinone 8%) administered once a day for 5 days
Number of subjects: 50
Study 15731312 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gel without vaginal progesterone) administered once a day for 5 days
Number of subjects: 50
Study 15731312 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Crinone 8%)
Number of subjects: 50
Study 11568372 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg bolus followed by 0.06 mg/kg/h continuous infusion)
Number of subjects: 33
Study 11568372 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.2 mg/kg bolus followed by 0.06 mg/kg/h continuous infusion)
Number of subjects: 33
Study 11568372 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and morphine infusion (10 microg/kg/h)
Number of subjects: 33
Study 11568372 — intervention group
Group type: COMPARATOR
Intervention: Placebo and morphine infusion (10 microg/kg/h)
Number of subjects: 33
Study 9643277 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril treatment initiated intravenously within 24 hours after acute myocardial infarction
Number of subjects: 0
Study 9643277 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril treatment
Number of subjects: 0
Study 7888290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 micrograms
Number of subjects: 0
Study 7888290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 micrograms
Number of subjects: 0
Study 7888290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 micrograms
Number of subjects: 0
Study 7888290 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms
Number of subjects: 0
Study 7888290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 micrograms twice daily for 3.5 days
Number of subjects: 0
Study 17171886 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-HES (hydroxyethyl starch solution, ratio 1:1, n = 15)
Number of subjects: 45
Study 17171886 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-RL (Ringer's lactate, ratio 2.5:1, n = 15)
Number of subjects: 45
Study 17171886 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 45
Study 30535100 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic therapy
Number of subjects: 604
Study 30535100 — intervention group
Group type: COMPARATOR
Intervention: 14 days of antibiotic therapy
Number of subjects: 604
Study 27840299 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) administered over the lumbar paraspinal muscles for 60 minutes per day, three times per week, for 4 consecutive weeks
Number of subjects: 30
Study 27840299 — intervention group
Group type: COMPARATOR
Intervention: Control group received muscle stimulation at the minimal sensory threshold intensity
Number of subjects: 30
Study 26004718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepsil
Number of subjects: 0
Study 26004718 — intervention group
Group type: EXPERIMENTAL
Intervention: Safoof-e-katira
Number of subjects: 0
Study 26004718 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 24290290 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 678
Study 24290290 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent of body fat
Number of subjects: 678
Study 24290290 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 678
Study 24290290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function
Number of subjects: 678
Study 24290290 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma severity/control
Number of subjects: 678
Study 24290290 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy
Number of subjects: 678
Study 24290290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to cockroach
Number of subjects: 678
Study 22428490 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion at 50 microg/min
Number of subjects: 117
Study 22428490 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine infusion at 100 microg/min
Number of subjects: 117
Study 19438480 — intervention group
Group type: EXPERIMENTAL
Intervention: Number needed to treat (NNT)
Number of subjects: 0
Study 19438480 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute risk reduction
Number of subjects: 0
Study 17606655 — intervention group
Group type: EXPERIMENTAL
Intervention: Columbia Classification Algorithm for Suicide Assessment (C-CASA)
Number of subjects: 427
Study 14971967 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (ULT)
Number of subjects: 14
Study 14971967 — intervention group
Group type: COMPARATOR
Intervention: Sham-ultrasound (CON)
Number of subjects: 14
Study 11180314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized controlled trials
Number of subjects: 0
Study 9040811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.375%
Number of subjects: 45
Study 9040811 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile physiologic saline)
Number of subjects: 45
Study 7946890 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 36
Study 7946890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 3068050 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of epinephrine plus polidocanol (group A)
Number of subjects: 72
Study 3068050 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (group B)
Number of subjects: 72
Study 28836373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Advice plus Smartphone Application Group
Number of subjects: 162
Study 28836373 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle Advice Only Group
Number of subjects: 162
Study 27879654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 27879654 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 27879654 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 24963731 — intervention group
Group type: COMPARATOR
Intervention: Patient Information Leaflet (PIL)
Number of subjects: 1497
Study 24963731 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 minutes of Brief Advice (BA)
Number of subjects: 1497
Study 24963731 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes of Brief Lifestyle Counseling (BLC)
Number of subjects: 1497
Study 22901498 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 555
Study 22901498 — intervention group
Group type: COMPARATOR
Intervention: Right ventricle‐to‐pulmonary artery shunt
Number of subjects: 555
Study 19785618 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% SCG
Number of subjects: 60
Study 19785618 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% SCG
Number of subjects: 60
Study 19785618 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% SCG
Number of subjects: 60
Study 19785618 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no SCG)
Number of subjects: 60
Study 19785618 — intervention group
Group type: EXPERIMENTAL
Intervention: SCG (all concentrations)
Number of subjects: 60
Study 18285316 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 400/100 mg + saquinavir 1000 mg twice daily (arm A)
Number of subjects: 48
Study 18285316 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 400/100 mg + saquinavir 600 mg twice daily (arm B)
Number of subjects: 48
Study 18285316 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 266/66 mg + saquinavir 1000 mg twice daily (arm C)
Number of subjects: 48
Study 18285316 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 266/66 mg + saquinavir 600 mg twice daily (arm D)
Number of subjects: 48
Study 15807813 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide adhesive
Number of subjects: 11
Study 15807813 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid adhesive
Number of subjects: 11
Study 11956422 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.7Fr multi-length stent
Number of subjects: 97
Study 11956422 — intervention group
Group type: EXPERIMENTAL
Intervention: 7Fr multi-length stent
Number of subjects: 97
Study 11956422 — intervention group
Group type: COMPARATOR
Intervention: No stent
Number of subjects: 97
Study 10215657 — intervention group
Group type: EXPERIMENTAL
Intervention: W/O/W of small IPSO microdroplets (30 micrometers in diameter) containing 60 mg of epirubicin (group A)
Number of subjects: 32
Study 10215657 — intervention group
Group type: EXPERIMENTAL
Intervention: W/O/W of large IPSO microdroplets (70 micrometers) containing 60 mg of epirubicin (group B)
Number of subjects: 32
Study 7705673 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu IL‐3 administered after chemotherapy (250 and 500 micrograms)
Number of subjects: 18
Study 7705673 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu IL‐3 administered before chemotherapy (50 micrograms)
Number of subjects: 18
Study 7705673 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu IL‐3 (50 micrograms)
Number of subjects: 18
Study 7705673 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu IL‐3 (250 and 500 micrograms)
Number of subjects: 18
Study 2568661 — intervention group
Group type: EXPERIMENTAL
Intervention: CM6912 (ethyl loflazepate) 1 mg twice daily (CM-1 group)
Number of subjects: 0
Study 2568661 — intervention group
Group type: EXPERIMENTAL
Intervention: CM6912 (ethyl loflazepate) 2 mg once daily (CM-2 group)
Number of subjects: 0
Study 2568661 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (DZP) 2 mg three times daily
Number of subjects: 0
Study 781206 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusion
Number of subjects: 101
Study 781206 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma or conventional supportive care
Number of subjects: 101
Study 30227936 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured counseling with an emphasis on LARC by a family planning specialist
Number of subjects: 121
Study 30227936 — intervention group
Group type: COMPARATOR
Intervention: Routine postpartum care
Number of subjects: 121
Study 27330023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg twice daily for four days then 4 mg twice daily for three days
Number of subjects: 41
Study 27330023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 27330023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 41
Study 24585205 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint crisis plans
Number of subjects: 41
Study 22453774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough Aid
Number of subjects: 74
Study 21078804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived stem cells (group A)
Number of subjects: 15
Study 21078804 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood-derived stem cells (group B)
Number of subjects: 15
Study 21078804 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone (group C)
Number of subjects: 15
Study 18507748 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous red blood cells (RBCs) derived from umbilical cord blood (UCB)
Number of subjects: 0
Study 18507748 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic transfusions
Number of subjects: 0
Study 15801015 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasterone 200 mg/day
Number of subjects: 55
Study 15801015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 12562577 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine, 7.5 mg/day
Number of subjects: 24
Study 12562577 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol, 2.5 mg/day
Number of subjects: 24
Study 11359749 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 227
Study 11359749 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 227
Study 9103735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 61
Study 9103735 — intervention group
Group type: COMPARATOR
Intervention: Control (attention, information, brief relaxation instructions)
Number of subjects: 61
Study 8466259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucagon (200 micrograms/kg)
Number of subjects: 23
Study 8466259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric medium chain triglyceride (MCT) (5 ml/kg)
Number of subjects: 23
Study 3709730 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gum
Number of subjects: 10
Study 3709730 — intervention group
Group type: COMPARATOR
Intervention: Hard gum
Number of subjects: 10
Study 31117092 — intervention group
Group type: EXPERIMENTAL
Intervention: Herniamesh mesh
Number of subjects: 232
Study 31117092 — intervention group
Group type: COMPARATOR
Intervention: Biological graft
Number of subjects: 232
Study 29378708 — intervention group
Group type: EXPERIMENTAL
Intervention: Plazomicin 10 mg/kg
Number of subjects: 145
Study 29378708 — intervention group
Group type: EXPERIMENTAL
Intervention: Plazomicin 15 mg/kg
Number of subjects: 145
Study 29378708 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 750 mg
Number of subjects: 145
Study 27310327 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2409 (0.001 to 3.0 mg/kg)
Number of subjects: 57
Study 27310327 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2409 (0.01 to 3.0 mg/kg)
Number of subjects: 57
Study 27310327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 25423041 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 1985
Study 25423041 — intervention group
Group type: COMPARATOR
Intervention: Routine diagnostic algorithm (sputum microscopy and limited culture)
Number of subjects: 1985
Study 25423041 — intervention group
Group type: COMPARATOR
Intervention: Routine diagnostic algorithm
Number of subjects: 1985
Study 25423041 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF among HIV-infected participants
Number of subjects: 1985
Study 25423041 — intervention group
Group type: COMPARATOR
Intervention: Xpert MTB/RIF vs Routine diagnosis
Number of subjects: 1985
Study 21715138 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume mechanical ventilation (V(T), 6 mL/kg)
Number of subjects: 150
Study 21715138 — intervention group
Group type: COMPARATOR
Intervention: Conventional tidal volume mechanical ventilation (V(T), 10 mL/kg)
Number of subjects: 150
Study 19605504 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with Irinotecan (XI)
Number of subjects: 118
Study 19605504 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine with Cisplatin (XP)
Number of subjects: 118
Study 18495607 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg 10 min before operation
Number of subjects: 175
Study 18495607 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg 5 min before operation
Number of subjects: 175
Study 18495607 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg 1 min before operation
Number of subjects: 175
Study 18495607 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg/kg 10 min before operation
Number of subjects: 175
Study 18495607 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2 mg/kg (control group)
Number of subjects: 175
Study 15677599 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 9260
Study 15677599 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid
Number of subjects: 9260
Study 15677599 — intervention group
Group type: COMPARATOR
Intervention: Switching from valproic acid to divalproex
Number of subjects: 9260
Study 11240980 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with 20 mg of omeprazole or 30 mg of lansoprazole twice a day, 200 mg of clarithromycin three times a day, and 500 mg of amoxicillin three times a day for 1 week
Number of subjects: 261
Study 11240980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual high-dose lansoprazole (30 mg four times daily) and amoxicillin (500 mg four times daily) for 2 weeks
Number of subjects: 261
Study 11240980 — intervention group
Group type: COMPARATOR
Intervention: Initial treatment with triple therapy
Number of subjects: 261
Study 9772054 — intervention group
Group type: EXPERIMENTAL
Intervention: RCM (Rabeprazole 20 mg b.d., Amoxycillin 1 g b.d., Metronidazole 400 mg b.d.)
Number of subjects: 75
Study 9772054 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC (Rabeprazole 20 mg b.d., Amoxycillin 1 g b.d., Clarithromycin 500 mg b.d.)
Number of subjects: 75
Study 9772054 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM (Rabeprazole 20 mg b.d., Amoxycillin 1 g b.d., Metronidazole 400 mg b.d.)
Number of subjects: 75
Study 9772054 — intervention group
Group type: EXPERIMENTAL
Intervention: RC (Rabeprazole 20 mg b.d., Clarithromycin 500 mg b.d.)
Number of subjects: 75
Study 8145782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention group (20% of total caloric intake as fat)
Number of subjects: 76
Study 8145782 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 76
Study 3344944 — intervention group
Group type: EXPERIMENTAL
Intervention: oesophageal detector device
Number of subjects: 100
Study 1361746 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg), subcutaneously, three times a week for 24 weeks
Number of subjects: 91
Study 1361746 — intervention group
Group type: COMPARATOR
Intervention: Placebo, subcutaneously, three times a week for 24 weeks
Number of subjects: 91
Study 1361746 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg), subcutaneously, three times a week for 52 weeks
Number of subjects: 91
Study 1361746 — intervention group
Group type: COMPARATOR
Intervention: Placebo, subcutaneously, three times a week for 52 weeks
Number of subjects: 91
Study 70119 — intervention group
Group type: EXPERIMENTAL
Intervention: CT myelography
Number of subjects: 80
Study 70119 — intervention group
Group type: COMPARATOR
Intervention: Conventional myelography
Number of subjects: 80
Study 70119 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric compression of the cord in a narrow canal
Number of subjects: 80
Study 70119 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-root swelling
Number of subjects: 80
Study 70119 — intervention group
Group type: EXPERIMENTAL
Intervention: Disk herniation with occlusion of the corresponding foramen
Number of subjects: 80
Study 70119 — intervention group
Group type: EXPERIMENTAL
Intervention: No abnormalities in cord and nerve roots
Number of subjects: 80
Study 31086071 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EXP) promoting ACW with social and behavioral strategies
Number of subjects: 2649
Study 31086071 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (COM) participating only in data collection
Number of subjects: 2649
Study 28475670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanically washed allogenic RBCs
Number of subjects: 60
Study 28475670 — intervention group
Group type: COMPARATOR
Intervention: Standard care RBCs
Number of subjects: 60
Study 25547113 — intervention group
Group type: EXPERIMENTAL
Intervention: Training package including usual postgraduate course, additional training days, outreach visits, regional meetings, and access to a reporting system for occupational therapists.
Number of subjects: 71
Study 25547113 — intervention group
Group type: COMPARATOR
Intervention: Postgraduate course for occupational therapists only (Control).
Number of subjects: 71
Study 25547113 — intervention group
Group type: EXPERIMENTAL
Intervention: Training package (Experimental Intervention).
Number of subjects: 71
Study 23396736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) added to pegylated interferon-alpha-2a and ribavirin
Number of subjects: 72
Study 23396736 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon-alpha-2a and ribavirin (control group)
Number of subjects: 72
Study 21289606 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 0
Study 21289606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19827277 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 51
Study 19827277 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual conservative treatment: NSAIDs, local splinting, local heat)
Number of subjects: 51
Study 17094417 — intervention group
Group type: EXPERIMENTAL
Intervention: FP (5-FU 800 mg/m2/d in continuous infusion for 5 days and cisplatin 100 mg/m2 on day 1 or 2)
Number of subjects: 232
Study 17094417 — intervention group
Group type: COMPARATOR
Intervention: FLP (LV 100 mg/m2/d in bolus for 5 days, followed by 5-FU 350 mg/m2/d in 1 h infusion for 5 days and cisplatin 100 mg/m2 on day 1 or 2)
Number of subjects: 232
Study 17094417 — intervention group
Group type: EXPERIMENTAL
Intervention: FP
Number of subjects: 232
Study 17094417 — intervention group
Group type: COMPARATOR
Intervention: FLP
Number of subjects: 232
Study 15754082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity training using weight belts (mean 7.8 kg) in step-ups and chair rises
Number of subjects: 189
Study 15754082 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity training using elastic bands and dumbbells
Number of subjects: 189
Study 15754082 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (lower and upper extremity training)
Number of subjects: 189